Latest & greatest articles for breast cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer screening

161. Digital mammography: a screening modality for breast cancer

be required (personal communication Fuji Australia representative). CLINICAL NEED AND BURDEN OF DISEASE In Australia free mammographic screening is offered on a biennial basis to all asymptomatic women aged 50 to 69 years. Screening is also available to women aged over 40 on an annual basis if there is a strong family history of breast cancer. In the period 2000-2001 a total of 1,567,544 women attended a BreastScreen service with 1,063,479 (68%) in the target population, aged 50-69 years. Between (...) ). While screen-film mammography provides a powerful tool for early breast cancer detection, there are some reported fundamental limitations (D’Orsi 2002). These limitations relate to contrast characteristics, or the ability to discern subtle soft tissue density differences, and decreased sensitivity in detecting early malignancy in the dense breast. EFFECTIVENESS AND SAFETY ISSUES At the time of preparing this summary two randomised, controlled trials were identified (level II screening evidence

2005 Australia and New Zealand Horizon Scanning Network

162. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations

The effectiveness data were derived from a review of published studies. Modelling A decision analysis based on a micro-simulation model was used. For all women who developed breast cancer during their lifetime, the authors simulated their natural histories. This included the age at onset of the preclinical disease, the preclinical durations (via tumour growth rates), the age at onset of the clinical disease, and the subsequent survival time depending on age and tumour characteristics at detection. For more (...) , Parmigiani G. Optimisation of breast cancer screening strategies. In: Nikoulina M, Commenges D, editors. Probability, statistics and modeling in public health. New York: Springer; In press. Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Breast Neoplasms /mortality /prevention & Comparative Study; Cost-Benefit Analysis; Humans; Mammography /economics; Mass Screening /economics; Middle Aged; Models, Statistical; Monte Carlo Method; Palpation /economics; Quality-Adjusted Life Years

2005 NHS Economic Evaluation Database.

163. Toward optimal screening strategies for older women: costs, benefits, and harms of breast cancer screening by age, biology, and health status Full Text available with Trip Pro

began with a hypothetical cohort of women aged 50 and randomly assigned dates of death, preclinical and symptomatic breast cancer incidence, and uptake of first and subsequent screening mammograms. Women destined to get BC were assigned a date at which symptomatic illness would present (clinical presentation). If the tumour was detected before this time, the disease stage was calculated. Women developing BC were assigned an oestrogen receptor (ER) status and received treatment based on current (...) Factors; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms /diagnosis /epidemiology /prevention & Cost-Benefit Analysis; Disease Progression; Female; Humans; Life Expectancy; Mammography /economics; Mass Screening /economics /standards /utilization; Middle Aged; Models, Econometric; Monte Carlo Method; Neoplasm Staging; Sensitivity and Specificity; Stochastic Processes; Survival Analysis; Value of Life; control AccessionNumber 22005001262 Date bibliographic record published 30/04/2006 Date

2005 NHS Economic Evaluation Database.

164. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). (Abstract)

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Women genetically predisposed to breast cancer often develop the disease at a young age when dense breast tissue reduces the sensitivity of X-ray mammography. Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening.We did a prospective multicentre cohort study in 649 (...) women aged 35-49 years with a strong family history of breast cancer or a high probability of a BRCA1, BRCA2, or TP53 mutation. We recruited participants from 22 centres in the UK, and offered the women annual screening with CE MRI and mammography for 2-7 years.We diagnosed 35 cancers in the 649 women screened with both mammography and CE MRI (1881 screens): 19 by CE MRI only, six by mammography only, and eight by both, with two interval cases. Sensitivity was significantly higher for CE MRI (77

2005 Lancet

165. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. Full Text available with Trip Pro

using immunohistochemistry or in situ hybridization and included ERBB2, TP53, and MK167 expression and ERBB2 amplification data.Univariate and multivariate analyses of potential risk factors for distant recurrence of breast cancer and 10-year survival.Of the 1983 women with unilateral invasive breast cancer, data on tumor diameter were available for 1918 women. Women with cancerous tumors detected by mammography screening had better estimated 10-year distant disease-free survival than women (...) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. Selection of systemic adjuvant therapies for women diagnosed as having breast cancer is based on risk estimations for cancer recurrence. In such estimations, tumors detected by mammography screening are considered to be associated with a similar risk of recurrence as tumors of similar size found by other methods.To compare the risk of recurrence and survival among women with cancerous tumors

2004 JAMA

166. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. Full Text available with Trip Pro

with a clinical breast examination and once a year by mammography and MRI, with independent readings. The characteristics of the cancers that were detected were compared with the characteristics of those in two different age-matched control groups.We screened 1909 eligible women, including 358 carriers of germ-line mutations. Within a median follow-up period of 2.9 years, 51 tumors (44 invasive cancers, 6 ductal carcinomas in situ, and 1 lymphoma) and 1 lobular carcinoma in situ were detected. The sensitivity (...) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. The value of regular surveillance for breast cancer in women with a genetic or familial predisposition to breast cancer is currently unproven. We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women.Women who had a cumulative lifetime risk of breast cancer of 15 percent or more were screened every six months

2004 NEJM

167. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. Full Text available with Trip Pro

Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. To determine whether any increase in the incidence of breast cancer in women detected by mammography is compensated for by a drop in the incidence after age 69, years when women are no longer invited for screening.Population based cohort study of incidence of breast cancer during the introduction of nationwide screening programmes.Norway and Sweden.All women aged above 30 years (...) (1.4 and 2.9 million, respectively, in 2000).Changes in age specific incidence rates of invasive breast cancer associated with the introduction of the screening programmes.As a result of screening the recorded incidence of breast cancer in women aged 50-69 years increased by 54% in Norway and 45% in Sweden. There was no corresponding decline in incidence after the age of 69 years.Without screening one third of all invasive breast cancers in the age group 50-69 years would not have been detected

2004 BMJ

168. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. Full Text available with Trip Pro

Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. To investigate whether information on mammographic screening presented on websites by interest groups is balanced, is independent of source of funding, and reflects recent findings.Cross sectional study using a checklist with 17 information items.27 websites in Scandinavian and English speaking countries.The 13 sites from advocacy groups and the 11 from governmental institutions all (...) recommended mammographic screening, whereas the three from consumer organisations questioned screening (P = 0.0007). All the advocacy groups accepted industry funding, apparently without restrictions. In contrast the three consumer organisations acknowledged the risk of bias related to industry funding, and two of them did not accept such funding at all. Advocacy groups and governmental organisations favoured information items that shed positive light on screening. The major harms of screening

2004 BMJ

169. Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening

Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Breast ductal lavage and fiberoptic ductoscopy (...) for breast cancer diagnosis and screening. Lansdale: HAYES, Inc.. Directory Publication. 2004 Authors' objectives Breast ductal lavage (DL) and fiberoptic ductoscopy (FDS) are used to evaluate patients at risk for breast cancer. DL involves collection of breast ductal epithelial cells for cytological analysis, and FDS involves direct visualization of the breast duct lining with cytology or biopsy of abnormalities. These procedures are intended to be used in conjunction with clinical breast examination

2004 Health Technology Assessment (HTA) Database.

170. MRI screening for breast cancer in genetically high-risk women

of breast cancers detected were small ranging from 1.6 to 17 per cent of all women enrolled. Most of the studies were conducted on relatively small numbers of women, the largest number of participants being 1,848. Project page URL INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms /diagnosis /genetics; Female; Genetic Predisposition to Disease; Magnetic Resonance Imaging; Mammography; Mass Screening /methods Language Published English Country (...) be of particular use as a breast screening modality in women considered to be at high-risk of developing breast cancer who tend to develop disease at a significantly younger age and are usually pre-menopausal. These women, due to their age, have high-density breast tissue and therefore are difficult to screen utilising mammography. Women considered to be at high-risk of developing breast cancer include those with a familial or personal history of breast or ovarian cancer, or women with a demonstrated germ-line

2004 Health Technology Assessment (HTA) Database.

171. Should the French breast cancer screening programme be extended to women aged 40-49? Update

. This is an update of the ANAES 1999 guidelines. Authors' conclusions No extension of the French breast cancer screening programme to women aged 40-49 should be envisaged until efficacy and cost-effectiveness in older women (50-74 years) have been proven. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms /diagnosis; Mammography; Mass Screening Language Published French Country of organisation France English Summary English summary available Address for correspondence 2 (...) Should the French breast cancer screening programme be extended to women aged 40-49? Update Should the French breast cancer screening programme be extended to women aged 40-49? Update Should the French breast cancer screening programme be extended to women aged 40-49? Update L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2004 Health Technology Assessment (HTA) Database.

172. Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer

trials. More robust research on the effectiveness and costs of technologically advanced infrared thermography devices for population screening and diagnostic testing of breast cancer is needed, and the conclusions of this review should be revisited in the face of additional reliable evidence. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms /diagnosis; Mass Screening; Thermography Language Published English Country of organisation New Zealand Address (...) Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Kerr J Record Status This is a bibliographic record of a published health technology

2004 Health Technology Assessment (HTA) Database.

173. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. (Abstract)

Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. The long term effect of mammographic service screening is not well established. We aimed to assess the long-term effect of mammographic screening on death from breast cancer, taking into account potential biases from self-selection, changes in breast cancer incidence, and classification of cause of death.We compared deaths from breast cancer diagnosed in the 20 (...) years before screening was introduced (1958-77) with those from breast cancer diagnosed in the 20 years after the introduction of screening (1978-97) in two Swedish counties, in 210000 women aged 20-69 years. We also compared deaths from all cancers and from all causes in patients diagnosed with breast cancer in the 20 years before and after screening was introduced. In the analysis, data were stratified into age-groups invited for screening (40-69 years) and not invited (20-39 years

2003 Lancet

174. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer

' objectives The objective of this Assessment is to evaluate the effectiveness of magnetic resonance imaging (MRI) of the breast for screening asymptomatic women thought to be at high risk of breast cancer due to genetic risk. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms /diagnosis; Magnetic Resonance Imaging; Mass Screening Language Published English Country of organisation United States Address for correspondence BlueCross BlueShield Association, Technology (...) Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality

2003 Health Technology Assessment (HTA) Database.

175. The safety net: a cost-effective approach to improving breast and cervical cancer screening

The safety net: a cost-effective approach to improving breast and cervical cancer screening Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

176. Screening for prostate, breast and colorectal cancer in renal transplant recipients

Screening for prostate, breast and colorectal cancer in renal transplant recipients Screening for prostate, breast and colorectal cancer in renal transplant recipients Screening for prostate, breast and colorectal cancer in renal transplant recipients Kiberd B A, Keough-Ryan T, Clase C M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The paper examines the cost-effectiveness of specific screening for prostate, breast and colorectal cancer for patients who have received a renal transplant. Breast cancer screening comprised a mammogram every 18 months. Prostate cancer screening involved an annual digital rectal examination and a prostate specific antigen assay. The screening programme for colorectal cancer required a faecal

2003 NHS Economic Evaluation Database.

177. News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer. (Abstract)

News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer. In the late 1990s, 3 events pertaining to breast cancer prevention received considerable attention in the US news media: a National Institutes of Health (NIH) consensus panel recommended against routine screening mammography for women in their 40s (January 1997), the National Cancer Institute (NCI) subsequently reversed the recommendation (March 1997), and an NCI-sponsored (...) study demonstrated the efficacy of tamoxifen in the primary prevention of breast cancer (April 1998).To examine how the major US news media covered the potential benefits and harms of 2 breast cancer preventive strategies.Content analysis of US news stories reporting on the breast cancer prevention events. We used Lexis-Nexis to search for print news stories in the 10 highest-circulation US newspapers and requested transcripts from 3 major television networks to obtain all relevant news coverage

2002 JAMA

178. Screening for breast cancer

mammography to a baseline clinical breast examination in women aged 40 to 49 at study entry and found no difference in breast cancer mortality. The role of breast self-examination in reducing breast cancer mortality has been evaluated in 2 randomized controlled trials and 1 non-randomized controlled trial, and none have shown benefit. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms /prevention & Breast Self-Examination; Mammography; Mass Screening; control Language (...) Screening for breast cancer Screening for breast cancer Screening for breast cancer Humphrey L, Chan B K S, Detlefsen S, Helfand M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humphrey L, Chan B K S, Detlefsen S, Helfand M. Screening for breast cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services

2002 Health Technology Assessment (HTA) Database.

179. Customer fee and participation in breast-cancer screening. (Abstract)

Customer fee and participation in breast-cancer screening. Until 1997, breast screening by mammography was free for all women living in Turku, Finland. After this date, women born in certain years had to pay to be screened. We did a retrospective study, using data obtained from Statistics Finland, to ascertain whether or not the introduction of a fee affected attendance. We also assessed the effect of socioeconomic status on attendance. Our findings show that people who had to pay (...) for mammography attended less often than women who were entitled to free screening, irrespective of their socioeconomic status.

2001 Lancet

180. Cochrane review on screening for breast cancer with mammography. (Abstract)

Cochrane review on screening for breast cancer with mammography. In 2000, we reported that there is no reliable evidence that screening for breast cancer reduces mortality. As we discuss here, a Cochrane review has now confirmed and strengthened our previous findings. The review also shows that breast-cancer mortality is a misleading outcome measure. Finally, we use data supplemental to those in the Cochrane review to show that screening leads to more aggressive treatment.

2001 Lancet